Your browser is no longer supported. Please, upgrade your browser.
Settings
VRX Valeant Pharmaceuticals International, Inc. daily Stock Chart
VRX [NYSE]
Valeant Pharmaceuticals International, Inc.
Index- P/E- EPS (ttm)-5.40 Insider Own2.30% Shs Outstand350.70M Perf Week-9.64%
Market Cap8.51B Forward P/E6.87 EPS next Y3.53 Insider Trans0.88% Shs Float347.66M Perf Month9.32%
Income-1892.00M PEG- EPS next Q0.78 Inst Own66.80% Short Float4.75% Perf Quarter57.91%
Sales8.61B P/S0.99 EPS this Y158.60% Inst Trans20.01% Short Ratio1.97 Perf Half Y16.18%
Book/sh12.61 P/B1.92 EPS next Y6.13% ROA-2.40% Target Price21.43 Perf Year56.58%
Cash/sh2.59 P/C9.36 EPS next 5Y2.19% ROE-18.80% 52W Range10.94 - 27.79 Perf YTD16.79%
Dividend- P/FCF5.48 EPS past 5Y66.20% ROI9.80% 52W High-12.67% Beta-0.34
Dividend %- Quick Ratio0.90 Sales past 5Y20.20% Gross Margin70.70% 52W Low121.85% ATR0.96
Employees20700 Current Ratio1.20 Sales Q/Q-5.40% Oper. Margin-28.70% RSI (14)55.02 Volatility4.79% 3.70%
OptionableYes Debt/Eq5.89 EPS Q/Q-528.60% Profit Margin-10.70% Rel Volume0.67 Prev Close24.72
ShortableYes LT Debt/Eq5.71 EarningsMay 08 BMO Payout- Avg Volume8.37M Price24.27
Recom2.80 SMA200.09% SMA5014.74% SMA20036.00% Volume5,587,939 Change-1.82%
Jun-22-18Downgrade TD Securities Buy → Hold
Apr-06-18Upgrade Mizuho Underperform → Neutral $10 → $15
Jan-24-18Initiated Goldman Sell $18
Jan-16-18Reiterated H.C. Wainwright Buy $17 → $24
Dec-15-17Reiterated Mizuho Underperform $7 → $10
Dec-14-17Downgrade JP Morgan Neutral → Underweight
Aug-03-17Reiterated RBC Capital Mkts Sector Perform $19 → $21
Jun-16-17Initiated Cantor Fitzgerald Overweight $18
May-10-17Reiterated RBC Capital Mkts Sector Perform $18 → $19
Apr-20-17Reiterated JP Morgan Neutral $15 → $10
Mar-23-17Reiterated RBC Capital Mkts Sector Perform $21 → $18
Mar-06-17Reiterated Rodman & Renshaw Neutral $23 → $17
Feb-27-17Reiterated Mizuho Underperform $11 → $9
Feb-14-17Reiterated RBC Capital Mkts Sector Perform $29 → $22
Feb-10-17Reiterated Barclays Equal Weight $34 → $20
Jan-04-17Reiterated Piper Jaffray Underweight $16 → $11
Dec-15-16Downgrade Morgan Stanley Overweight → Equal-Weight $25 → $17
Nov-23-16Downgrade Mizuho Neutral → Underperform $25 → $11
Nov-14-16Reiterated Deutsche Bank Hold $29 → $24
Nov-10-16Reiterated Morgan Stanley Overweight $42 → $25
Jun-22-18 06:47PM  Cramer's lightning round: I don't like Snap's ownership structure CNBC
Jun-21-18 10:53AM  The woman behind 'female Viagra' sold her company for $1 billion then got it back for free CNBC
Jun-20-18 08:08AM  There Go Those Drug Companies Inventing New Diseases Again Forbes
Jun-19-18 02:33PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valeant Pharmaceuticals International, Inc. - VRX PR Newswire
12:03PM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Valeant Pharmaceuticals International, Inc. (VRX) PR Newswire
11:17AM  Valeant Down as FDA Refuses to Approve Duobrii For Psoriasis Zacks
09:53AM  Valeant's FDA Letter: Don't Write Off the Stock Yet Barrons.com
09:19AM  Company News For Jun 19, 2018 Zacks
Jun-18-18 05:17PM  Why Valeant Pharmaceuticals' Stock Tumbled 12.3% Today Motley Fool -12.29%
05:02PM  What Happened in the Stock Market Today Motley Fool
01:46PM  Valeants Rebound Falters After Key Drug Is Rejected Bloomberg
01:04PM  Valeant Stock Was Having a Pretty Good 2018Until Today Fortune
12:26PM  Valeant Pharmaceuticals Intl Inc Shares Sink on Psoriasis Treatment Rejection by FDA InvestorPlace
11:41AM  FDA declines to approve Valeant's plaque psoriasis lotion Reuters
10:02AM  FDA Letter May Not Hamper Valeant for Long Barrons.com
09:28AM  Stocks to Watch: Apple, Facebook, Alphabet, Comcast, GE, GM, Wynn, Valeant, Chevron, Perry Ellis The Wall Street Journal
08:13AM  Valeant shares drop 5% after FDA fails to approve plaque psoriasis lotion MarketWatch
08:00AM  FDA Issues Complete Response Letter For DUOBRII (Halobetasol Propionate and Tazarotene) Lotion PR Newswire
Jun-15-18 10:26AM  MARKETS: Here's why stocks are dropping right now Yahoo Finance Video
09:56AM  Can Sprout Pharmas Latest Revival Really Boost VRX Stock? InvestorPlace
09:32AM  Teva Pharmaceutical Industries Limited Stock Still Is a Deep Value Play InvestorPlace
09:11AM  Zacks Value Investor Highlights: Gilead Sciences, Biogen, Celgene, Lannett and Valeant Zacks
Jun-14-18 08:00AM  Bausch + Lomb Launches Soothe® Xtra Protection Preservative Free Lubricant Eye Drops PR Newswire
Jun-13-18 06:41PM  Drug Stocks: The Next Hot Industry or Value Traps? Zacks
08:58AM  What Cindy Eckert has planned with Sprout, Addyi back in hands American City Business Journals
05:00AM  The Womens Libido Pill Is Back, and So Is the Controversy Bloomberg
Jun-12-18 05:16PM  Moody's: Bond covenant protections weaken as private equity scores hit record-worst Moody's
08:00AM  Bausch + Lomb Introduces Ocuvite® Blue Light Eye Vitamins PR Newswire
Jun-11-18 08:20AM  Today's Research Reports on Trending Tickers: Valeant Pharmaceuticals and OPKO Health ACCESSWIRE
Jun-08-18 06:00PM  Securities Class Action Filed on Behalf of Persons or Entities That Traded Certain Derivative Securities of Valeant Pharmaceuticals International, Inc. During the Period January 4, 2013 Through August 11, 2016, Inclusive Business Wire
01:19PM  Valeant Pharmaceuticals Intl Inc Has New Name But Same Problems InvestorPlace
Jun-07-18 09:19AM  Valeant (VRX) Up 19.3% Since Earnings Report: Can It Continue? Zacks
06:31AM  Is Valeant Pharmaceuticals International, Inc. a Buy? Motley Fool
Jun-06-18 10:21PM  Replay: Jim Cramer on Bank Stocks, Cruise Stocks and Valeant Pharmaceuticals TheStreet.com +7.72%
12:19PM  Jim Cramer: Barclays' $29 Price Target on Valeant Is 'Very Right' TheStreet.com
11:57AM  Cramer now sees value in drug stock Valeant after its CEO 'delivered' CNBC
11:41AM  Valeant & Perrigo: Buy One, Skip the Other Barrons.com
11:37AM  Cramer now sees value in drug stock Valeant after its CEO... CNBC Videos
08:57AM  Morning Movers: Twitter Sinks on Offering, Valeant Gains on Upgrade Barrons.com
08:10AM  Today's Research Reports on Stocks to Watch: Co-Diagnostics and Valeant Pharmaceuticals ACCESSWIRE
Jun-05-18 08:25AM  Detailed Research: Economic Perspectives on Central European Media Enterprises, Valeant Pharmaceuticals International, Nice, NCS Multistage, NewLink Genetics, and Colliers International Group What Drives Growth in Today's Competitive Landscape GlobeNewswire +7.23%
Jun-01-18 04:15PM  Valeant Announces Closing Of Amended And Restated Credit Agreement Transaction And Senior Notes Offering, As Well As Redemption Of Existing Senior Notes PR Newswire
03:56PM  Key FDA Events in June Investors Need to Watch Out For Zacks
11:45AM  Valeant, Endo Both Buys in Specialty Pharma Barrons.com
May-31-18 08:30AM  Salix To Highlight New Clinical Data During Digestive Disease Week PR Newswire
May-29-18 10:35AM  EYEG: 3 of 4 FDA Questions Answered, OBG-PRK Study On-Track for Q3 Start Zacks Small Cap Research
May-25-18 01:18PM  Tesla is near the top of list of stocks that Wall Street is most confused about CNBC
May-23-18 01:00AM  [$$] Jury Finds Former Valeant Exec Guilty on Charges Related to Kickback Scheme The Wall Street Journal
12:15AM  [$$] A closer look at the great Maryland pension fees debate Financial Times
May-22-18 02:15PM  Former CEO of Hatboro mail-order pharmacy convicted of fraud, money laundering charges American City Business Journals
02:05PM  [$$] Former Valeant Exec Found Guilty on Charges Related to Kickback Scheme The Wall Street Journal
01:44PM  Ex-Valeant, Philidor executives convicted of kickback scheme Reuters
01:25PM  Ex-Valeant Executive Guilty of Taking Pharmacy CEOs Bribe Fortune
01:18PM  Jury Finds Former Valeant Exec Guilty on Charges Related to Kickback Scheme The Wall Street Journal
10:58AM  Ex-Valeant Executive Guilty of Taking Pharmacy CEOs Bribe Bloomberg
May-21-18 11:00PM  [$$] Leveraged loan rush sees borrowers gain balance of power Financial Times
May-19-18 04:10PM  Cantor Fitzgerald: 18 Drug Companies With Catalysts Worth Watching Benzinga
May-18-18 12:35AM  Ackman Has a Point About United Technologies Corporation Stock InvestorPlace
May-17-18 05:00PM  Valeant Announces Pricing Of Private Offering Of Notes PR Newswire
10:48AM  Valeant Pharmaceuticals International, Inc -- Moody's assigns Caa1 to Valeant's unsecured notes; outlook stable Moody's
07:22AM  Valeant launches $750 million bond offering, increases planned Term B loan borrowing MarketWatch
07:15AM  Valeant Announces Launch Of Private Offering Of Notes And Upsize Of Term Loans PR Newswire
May-16-18 08:20AM  Today's Research Reports on Trending Tickers: Celgene and Valeant Pharmaceuticals ACCESSWIRE
May-15-18 02:44PM  Valeant Ex-CEO Wasn't Swayed by Philidor Warning, Witness Says Bloomberg
12:40PM  Valeant Pharmaceuticals International, Inc -- Moody's assigns Ba3 to Valeant's new credit facilities; outlook stable Moody's
11:00AM  Valeant: Turning Around or Just Spinning? Barrons.com
09:23AM  Stocks to Watch: Home Depot, Amazon, Symantec, Wynn, CBS, Viacom, Tesla, Ford, Micron, Valeant The Wall Street Journal
08:00AM  Valeant to Participate at the 2018 Barclays High Yield Bond and Syndicated Loan Conference PR Newswire
07:49AM  VRX Investor Alert: Kyros Law Announces that it is Filing Legal Claims on Behalf of Valeant Pharmaceuticals Intl (NYSE: VRX) Investors PR Newswire
07:00AM  Bill Ackmans Big Deals Dont Look Better in Hindsight Bloomberg
May-14-18 03:03PM  Ex-Valeant Official Says He Suspected Secret Financial Stake Bloomberg
May-13-18 10:18AM  Barron's Picks And Pans: Arista, Kroger, SeaWorld, Valeant And More Benzinga
May-11-18 10:14AM  AT&T CEO calls Cohen hiring a mistake, Barclays CEO pays fine, JPM reportedly focuses on electronic trading Yahoo Finance Video
May-10-18 03:21PM  Valeant (VRX) Rallies on Earnings Beat in Q1, Raises View Zacks
08:30AM  Valeant To Participate At 2018 Bank Of America Merrill Lynch Healthcare Conference PR Newswire
07:16AM  Valeant will borrow more than $3.82 bln MarketWatch
07:00AM  Valeant To Seek Refinancing of its Existing Credit Agreement PR Newswire
May-09-18 01:07PM  Valeant Earnings: One Day Later, Shares Are Still Rising Barrons.com
11:34AM  Jim Cramer on Bausch Health: This Stock Is a Buy TheStreet.com
09:05AM  Wednesdays Vital Data: Valeant Pharmaceuticals Intl Inc (VRX), Walt Disney Co (DIS) and Citigroup Inc (C) InvestorPlace
08:52AM  Valeant Pharmaceuticals (VRX) Catches Eye: Stock Jumps 8.9% Zacks
08:30AM  Today's Research Reports on Trending Tickers: OPKO Health and Valeant Pharmaceuticals ACCESSWIRE
07:00AM  4 Top Stock Trades for Wednesday Morning InvestorPlace
06:57AM  Valeant will get a new name to shed its scandals, but will it work? MarketWatch
May-08-18 07:19PM  Valeant Pharma CEO: Seeing organic growth for first time ... CNBC Videos +8.87%
07:00PM  Cramer Remix: GE just got a huge breakthe stock may have bottomed CNBC
06:53PM  For the first time since 2015, we're seeing organic growt... CNBC Videos
06:20PM  For the first time since 2015, we're seeing organic growth: Valeant Pharma CEO CNBC
04:29PM  Why Expeditors International of Washington, Valeant Pharmaceuticals International, and SeaWorld Entertainment Jumped Today Motley Fool
04:11PM  Dow Trims Earlier Losses, Finishes Slightly Higher After Volatile Session TheStreet.com
03:30PM  Valeant: A 'Turnaround for the Ages'? Barrons.com
03:02PM  Valeant Pharmaceuticals' Turnaround Gains Momentum With a Better-Than-Expected First Quarter Motley Fool
02:06PM  Valeant Pharmatceuticals Debt Wont Be Fooled by a Name Change InvestorPlace
01:59PM  One of Tampa Bays biggest health care manufacturers changes its name American City Business Journals
12:06PM  Valeant tries to leave the past behind with name change, shares surge Reuters
11:58AM  Valeant tries to leave the past behind with name change, shares surge Reuters
10:57AM  Top 3 Companies Owned by Valeant Investopedia
10:51AM  [$$] Valeant Returns to Organic Revenue Growth The Wall Street Journal
10:43AM  Valeant Upside, Shire Buyout Don't Rally Pharma Stocks Barrons.com
10:29AM  Can a Bold Name Change Help Valeant Escape Its Tarnished Reputation? TheStreet.com
Valeant Pharmaceuticals International, Inc. operates as a multinational, specialty pharmaceutical, and medical device company that develops, manufactures, and markets a range of pharmaceuticals, over-the-counter (OTC) products, and medical devices. The company operates through three segments: Bausch + Lomb/International, Branded Rx, and U.S. Diversified Products. The Bausch + Lomb/International segment provides pharmaceutical products, OTC products, and medical device products, primarily consist of Bausch + Lomb products, with a focus on the vision care, surgical, consumer, and ophthalmology Rx products in the United States; and pharmaceutical products, generic pharmaceutical products, OTC products, medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia and New Zealand, Latin America, Africa, and the Middle East. The Branded Rx segment sells gastrointestinal and dermatological products in the United States. The U.S. Diversified Products segment offers pharmaceutical products, OTC products, and medical device products in the areas of neurology and certain other therapeutic classes, including aesthetics. The company was founded in 1983 and is headquartered in Laval, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DE SCHUTTER RICHARD UDirectorMay 15Buy21.8315,000327,450133,383May 17 04:43 PM
Herendeen PaulEVP and CFOMar 13Buy16.1015,000241,470231,492Mar 13 04:43 PM
PAPA JOSEPH CCHAIRMAN & CEOMar 13Buy16.0530,000481,500719,019Mar 13 04:38 PM
DE SCHUTTER RICHARD UDirectorMar 08Buy15.3410,000153,400106,062Mar 12 08:59 PM
Paulson JohnDirectorMar 06Buy15.407,066,629108,826,08720,839,035Mar 08 05:04 PM
Paulson JohnDirectorMar 06Sale15.407,066,629108,826,08713,772,406Mar 08 05:04 PM
DE SCHUTTER RICHARD UDirectorNov 17Buy14.3310,000143,30094,559Nov 21 06:26 PM
Paulson JohnDirectorNov 16Buy14.40344,2164,955,50621,183,251Nov 20 06:00 PM
Paulson JohnDirectorNov 16Sale14.39344,2164,952,82120,839,035Nov 20 06:00 PM
DE SCHUTTER RICHARD UDirectorAug 21Buy14.3310,000143,29682,379Aug 22 04:39 PM